Patent classifications
C12N15/52
Chemoautotrophic cells comprising an engineered carbon fixation pathway
The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest.
Adenylosuccinate synthetase and method for producing purine nucleotides using the same
The present disclosure relates to an adenylosuccinate synthetase variant, a microorganism containing the same, and a method for preparing purine nucleotides using the microorganism.
Adenylosuccinate synthetase and method for producing purine nucleotides using the same
The present disclosure relates to an adenylosuccinate synthetase variant, a microorganism containing the same, and a method for preparing purine nucleotides using the microorganism.
Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.
Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.
Production of Steviol Glycosides in Recombinant Hosts
The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.
Production of Steviol Glycosides in Recombinant Hosts
The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.
NOVEL ESTERASES AND USES THEREOF
The present invention relates to esterases, more particularly to esterase variants having improved activity and/or improved thermostability compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.
NOVEL ESTERASES AND USES THEREOF
The present invention relates to esterases, more particularly to esterase variants having improved activity and/or improved thermostability compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.
BIOLOGICAL DEVICES AND METHODS OF USE THEREOF TO PRODUCE STEVIOL GLYCOSIDES
Described herein are devices and methods for increasing the production of steviol glycosides, which have industrial and economic value. The steviol glycosides produced by the devices and methods disclosed herein do not require the ultra purification that is common in conventional or commercial methods and do not have a bitter aftertaste, making them better suited as flavor-enhancing additives to food, pharmaceutical, and nutritional supplement products.